Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development

D Singh, D Dheer, A Samykutty, R Shankar - Journal of Controlled Release, 2021 - Elsevier
The antibody-drug conjugates (ADCs) are one the fastest growing biotherapeutics in
oncology and are still in their infancy in gastrointestinal (GI) cancer for clinical applications to …

Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis

Y Wu, H Ni, D Yang, Y Niu, K Chen, J Xu… - … -Research and Practice, 2021 - Elsevier
Although mutations of genes are crucial events in tumorigenesis and development, the
association between gene mutations and lung cancer metastasis is still largely unknown …

In Silico Screening of Mutated K‐Ras Inhibitors from Malaysian Typhonium flagelliforme for Non‐Small Cell Lung Cancer

A Fatima, HF Yee - Advances in Bioinformatics, 2014 - Wiley Online Library
K‐ras is an oncogenic GTPase responsible for at least 15–25% of all non‐small cell lung
cancer cases worldwide. Lung cancer of both types is increasing with an alarming rate due …

Clinical application of automatic gene chip analyzer (WEnCA-Chipball) for mutant KRAS detection in peripheral circulating tumor cells of cancer patients

SK Hsiung, SR Lin, HJ Chang, YF Chen… - Biomedical …, 2011 - books.google.com
KRAS is an important oncogene that participates in the mitogen-activated protein kinase
(MAPK) pathway. The MAPK pathway is involved in various cellular functions, including cell …

[PDF][PDF] Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems

AS Nagaraj - 2018 - helda.helsinki.fi
Cancer is a disease characterized by abnormal growth of cells in an uncontrolled manner.
Certain cancer cells have the potential to invade or spread into surrounding tissues, by a …